Inspraa 25mg and 50mg FC tablet
PDF Leaflet Revision Date: 01 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Reduce cardiovascular death risk in heart failure post-MI.
Dosage (summary)
Initial: 25 mg OD, Maintenance: 50 mg OD.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Potassium-sparing diuretics
- CYP3A4 inhibitors
- ACE inhibitors
- NSAIDs
Contraindications
- Hypersensitivity
- Hyperkalaemia
- Severe renal impairment
- Severe hepatic impairment
Common side effects
- Hyperkalaemia
- Dizziness
- Hypotension
- Cough
- Diarrhoea
Counselling Points
- Monitor potassium levels regularly
- Take with or without food
- Caution when driving due to dizziness
Serious warnings
- Risk of hyperkalaemia
- Monitor potassium levels
Important Disclaimer
The Inspraa 25mg and 50mg FC tablet professional information leaflet below is the property of Upjohn South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
